Articles On Creso Pharma (ASX:CPH)

Nedlands-based medical cannabis group Creso Pharma is back in an unwelcome spotlight after Federal authorities raided the broking firm of its chairman Adam Blumenthal.

The Creso Pharma Ltd (ASX: CPH) share price came under pressure this afternoon. This followed breaking news published by The Australian Financial Review involving the cannabis and psychedelics company’s non-executive chair, Adam Blumenthal...

EverBlu Capital raid tied to $160 million cannabis products group.

"The acquisition of the assets of ImpACTIVE was a major development for Creso Pharma as we saw significant potential based on the product suite and the strength of the management team," non-executive chairman Adam Blumenthal said.

Creso Pharma (CPH) records more than $800,000 of revenue in the fourth quarter from its Swiss business This represents a 126 per cent increase on the previous quarter according to a CHP statement Based on current performance, CPH believes...

The Creso Pharma Ltd (ASX: CPH) share price is on the move on Thursday. This comes as the cannabis and psychedelics company released a positive trading update for Q4 FY21. During early afternoon trade, Creso shares are swapping hands for 1...

“Demand for our human health product suite has increased recently, highlighting Creso Pharma’s ongoing shift from a product development focused company to a diversified commercial life sciences company with a global reach,” Adam Blumenthal...

Instead of a chocolate advent calendar this year, Californians can get their hands on a cannabis calendar with edibles, prerolls, grams of flower and four days of cannabis accessories. “We’ve seen the success of unique advent calendars in o...

With a new Republican-led bill to be introduced in Congress legalising cannabis use in the US, Creso Pharma is well positioned to take advantage of any uptick in demand.  Australian medicinal cannabis company, Creso Pharma (ASX:CPH) is pos...

In a major step towards a Phase II clinical trial Halucenex has received favourable results from stability testing for its GMP grade psilocybin. Global medicinal cannabis company Creso Pharma (ASX:CPH) has announced its wholly-owned psyche...

“We will now finalise our CTA and submit to Health Canada in the coming weeks. Clinical Trial Authorisation is the final piece in the commencement of our planned initiatives, which will unlock a number of substantial opportunities for the c...

ASX cannabis shares were nothing short of a mixed bag last month. Several names did well but a large body of shares missed the benchmark completely. For some context, the S&P/ASX 200 Health Care index (ASX: XHJ) regained steam over th...

Creso Pharma is evaluating near-term opportunities for expansion in the US and will leverage the extensive scientific industry expertise of Dr Walker and the Scientific Advisory Committee to unlock value for shareholders.

Each week boutique corporate advisory firm EverBlu Capital explores different sectors and trends, along with which companies Stockhead readers should put on their watch list. As the cannabis industry continues to gain momentum globally, exe...

ASX biotech shares posted a month of solid gains in October, outpacing the wider market as a whole. For instance, the S&P/ASX 300 Pharmaceuticals & Biotechnology Index (ASPBKD) climbed around 6% after a sharp decline to start the...

Creso Pharma (CPH) enters a non-binding LOI with Innuana AG Switzerland Innuana is a licensed cannabis grower in Switzerland and might grow crops under Creso’s specifications. According to Creso, there will be 110,000 medical cannabis pati...

“Recent regulatory shifts in Switzerland have unlocked a significant opportunity for Creso Pharma and this collaboration with Innuana marks the first step in our expansion into the Swiss prescription market,” says director of international...

Shares in medicinal cannabis company Creso Pharma Ltd (ASX: CPH) are inching higher today, now changing hands at 12 cents apiece. Today’s 4.35% gain from the open builds on the past 2 days of trading. Over this time, the company has relea...

Actor Jim Belushi has partnered with – you guessed it – Dan Aykroyd on a tour through Oklahoma’s cannabis industry ahead of a Blues Brothers performance. “We believe that cannabis is one of the great, great medicines that can lead to a path...

The Creso Pharma Ltd (ASX: CPH) share price is gaining ground in early trading, currently up around 9% at 12 cents apiece. Creso Pharma shares are on the move as the company released a prospectus today, amid an acquisition that was comple...

Perth-based medicinal cannabis company Creso Pharma has snapped up a Canadian cannabidiol player as it looks to grow its presence in the North American market.

Today Creso Pharma’s (ASX:CPH) announced the acquisition of a range of CBD brand and product assets that deliver anti-inflammatory relief to professional and amateur athletes suffering from chronic muscle and joint pain.

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is higher by 0.7%. Notices from both the Australian and European Patent Offices have been received by Noxopharm (ASX:NOX), relating to...

Creso Pharma (CPH) enters an asset purchase agreement to acquire the ImpACTIVE Assets via a newly incorporated subsidiary, Creso ImpACTIVE Founded in 2019, ImpACTIVE is a Canadian life sciences company designed to provide alternative treat...

Creso Pharma will acquire ImpACTIVE’s assets to bolster its North American presence to progress market entry strategy. Global medicinal cannabis company, Creso Pharma (ASX:CPH), is making further inroads into the North American market after...

The Creso Pharma Ltd (ASX: CPH) share price is surging today, up 9% in morning trade. Below we take a look at the latest acquisition news that appears to be stoking interest in the ASX cannabis share. What acquisition was reported? The Cre...

“We are very excited to join the Creso Pharma group of companies. Creso has an established global footprint, existing sales channels and operations which will give us the framework to potentially significantly scale our own business to meet...

ASX cannabis shares were once one of the hottest sectors with no shortage of new pot stocks hitting the market. The Cann Group Ltd (ASX: CAN) share price, for example, skyrocketed almost 300% between September 2017 and January 2018 amid t...

Turn on, tune in and don’t drop out. The push to develop psychedelic drugs is gaining momentum, but not quite in the way the 1960s counter-culture figure Dr Timothy Leary intended. The late Harvard psychologist strongly advocated the use of...

Last week California Governor Gavin Newsom signed Assembly Bill (AB-45), formally permitting the sales of hemp-derived CBD products in the state. Hemp has been legalised at the US federal level since 2018, but state agencies have been slow...

The Creso Pharma Ltd (ASX: CPH) share price is sliding in afternoon trade today and now trades at 11.3 cents apiece. Whilst there’s been no market sensitive information released today, Creso Pharma shares are struggling despite the compan...

This is a major achievement as it exceeds industry average and is another key competitive advantage, underpinning Mernova’s potential expansion into new provinces and sales growth.

Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.

Over recent days, Creso Pharma (ASX: CPH) appears to have gained some significant momentum. Momentum includes three new purchase orders for Creso Pharma’s anibidiol® line of animal health products were signed today, to a value of $A$414,000...

Creso Pharma (ASX: CPH) just released its preliminary financial reports for the year, which as expected show a bunch of impairments, debt clean ups and other scary looking one off costs that come with a balance sheet clean up - these are al...

Creso Pharma (ASX: CPH | FRA: 1X8) is set to distribute its range of CBD and hemp animal health anibidiol® products throughout the US, following a deal signed with CERES Natural Remedies.

Once again, medicinal cannabis company Creso Pharma (ASX: CPH) keeps pleasantly surprising us. Today they have REALLY surprised us by announcing they have acquired a Psychedelics company.

Creso Pharma (ASX: CPH) will be the first ASX listed stock to acquire 100% of a psychedelics company. CPH is set to acquire Canada based Halucenex Life Sciences Inc., an established psychedelics company developing treatments for a range of...

Creso Pharma (ASX: CPH) is listing on the US markets within weeks (via an OTC listing), but a similar company called MindMed is listing on the NASDAQ in 8 hours from now.

Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfoli...

Creso Pharma (ASX:CPH) today announced its listing in the US, and the market is opening in around 12 hours - the US pool of investors is huge and they have a big appetite for psychedelics and cannabis stocks.

Creso Pharma (ASX: CPH)’s acquisition target Halucenex just picked up an extra 10g of ‘hard-to-access’ synthetic psilocybin - and now has 22.3g in total.

Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.

Creso Pharma Ltd (ASX:CPH | OTC:COPHF) has just confirmed two consecutive quarters of record revenue growth. CPH posted $1.71M revenue this quarter - up from $1.38M in the previous quarter - that’s 24% growth.

“The recently published report from the TGA highlights the ongoing shift and acceptance towards the use of psychedelic substances as alternative treatment routes and coincides with a pivotal step in the company’s USP 61 and USP 62 testing i...

The independent report by the TGA could potentially down-schedule the use of psychedelic substances, opening the door for Creso Pharma to capture the Australian market as a first mover. Global medicinal cannabis company, Creso Pharma (ASX:C...

The Creso Pharma [ASX:CPH] shares soared in early morning trade after the company announced its wholly-owned Canadian subsidiary, Mernova, secured over $800,000 in new purchase orders. The post Creso Pharma Shares Jumps 12% after Securing N...

The ASX 200 health stocks index (XHJ) is falling by 0.55% at the time of writing, compared to the broader ASX 200 index which fell by 0.50%. Fibrotic and inflammatory diseases-focused biotech, Pharmaxis (ASX:PXS), has just announced further...

Recurring orders from provincial Canadian partners highlight consumer demand for Mernova’s top quality product range.

The new purchase orders received by Creso’s subsidiary Mernova underpin the recent progress it has made in the Canadian cannabis market. Global medicinal cannabis company, Creso Pharma (ASX:CPH), is making further traction in Canada followi...